Kiyatec (Series C)
Funding Details
- Awarder
- Inbox
- Date Award
- December 12, 2022
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $18,000,000
Company Info
- Company Description
- KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company's Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for its investigational drug candidates across the majority of solid tumor types.
- Market
- Cancer Drug Development
- Location
- Greenville, South Carolina, USA
- Coinvestors
- Bruker Corporation, LabCorp, Seae Ventures, VentureSouth